Labs that matter — what to pull, when, how to read

Your doctor pulls H-b-A-1-c, sees five point four, and tells you you're fine. Three years later you're insulin-resistant with normal glucose. The lab wasn't wrong. It was the wrong lab. H-b-A-1-c is the LAST marker to break in the insulin resistance cascade — by the time it moves, you've already been metabolically dysfunctional for somewhere between five and fifteen years. The practitioner corpus is unanimous on this point: if you're using H-b-A-1-c as your screening tool, you're catching the disease after it's already won the first decade. [short pause] Insulin resistance progresses through a stable, predictable sequence. The pancreas compensates for cellular insulin resistance by secreting more insulin to keep glucose in range — this is the HYPERINSULINEMIC-EUGLYCEMIC stage. It can last a decade or longer. Fasting glucose stays normal. H-b-A-1-c stays normal. The patient looks healthy on every standard lab. The only thing that's already wrong is fasting insulin, which is climbing. The oral glucose tolerance test, or O-G-T-T, staging the practitioner corpus uses lays it out cleanly: in the early stages, post-glucose-load insulin spikes hard while glucose stays flat — the pancreas is doing extra work to maintain a normal-looking result. Stage four is when fasting blood sugar finally creeps above ninety to one hundred milligrams per deciliter alongside elevated fasting insulin. Stage five is when fasting glucose breaks one hundred even with the pancreas running at maximum. H-b-A-1-c follows fasting glucose. C-peptide and beta-cell function decline last. The lab you want is the one that moves first, not the one that moves last. [short pause] Then there's the red blood cell problem. H-b-A-1-c measures glucose bound to hemoglobin, which is a proxy for AVERAGE glucose over the lifespan of a red blood cell. The assumption is that every patient's red blood cells live roughly ninety to one hundred twenty days. They don't. Patients with longer-living red blood cells get an artificially elevated H-b-A-1-c — the practitioner consensus is that comparing ninety-day continuous glucose monitor averages to H-b-A-1-c reveals the A-1-c overstates blood glucose by zero point five to zero point eight percentage points in a substantial fraction of healthy patients. A reported five point seven might actually be a five point zero. Conversely, patients with rapid red blood cell turnover — athletes, certain anemias, recent blood loss — read artificially low. H-b-A-1-c is not the ground truth. It's a noisy proxy. [short pause] Now the panel that actually works. Pull all of the following at baseline, then re-pull at Week six and Week ten of the protocol. The first three are the leading edge — they move first when something is working, or breaking. First, FASTING INSULIN. Ideal range is two to six micro international units per milliliter; under ten is acceptable. This is pancreatic compensation load — the first marker to move. Expert tier. Next, HOMA-I-R. Ideal under one point zero; under one point five acceptable. The formula is fasting insulin multiplied by fasting glucose, divided by four hundred and five. It quantifies how hard the pancreas is working. Clinical tier. Third, the TRIGLYCERIDE TO H-D-L RATIO. Ideal at or below one point zero; above two point zero is an insulin resistance signal. This is the atherogenic index of plasma — it predicts L-D-L particle size and all-cause mortality. Clinical tier. Fasting glucose target is seventy-two to eighty-five milligrams per deciliter. It lags fasting insulin by years. It moves only after pancreas compensation fails. Clinical tier. H-b-A-1-c target is under five point four percent, interpreted with red blood cell context. It's a ninety-day glucose average via glycated hemoglobin — red-blood-cell-turnover dependent, and noisy. Clinical tier. O-G-T-T with insulin drawn at zero, thirty, sixty, and one hundred twenty minutes. The insulin peak should stay under thirty to fifty micro international units per milliliter at thirty minutes, and return to baseline by one hundred twenty minutes. This catches Stage two and three insulin resistance years before fasting glucose breaks. Expert tier. C-peptide target is zero point eight to three point one nanograms per milliliter. It measures beta-cell function. It drops late-stage as the pancreas exhausts. Clinical tier. And finally, continuous glucose monitor, or C-G-M, fourteen-day average plus post-meal excursion data. Pre-meal floor seventy-two to ninety milligrams per deciliter; postprandial spike under thirty milligrams per deciliter above baseline; return to baseline within two hours. This is real-time pancreatic response under actual dietary load. Expert tier. [short pause] The O-G-T-T-with-insulin variant matters more than the standard O-G-T-T. A standard O-G-T-T only catches you at Stage four or five — when fasting glucose is already abnormal. The fasted-and-thirty-minute-post-glucose-load INSULIN measurement catches you at Stage two, when the pancreas is screaming to keep glucose flat. That's the window where intervention reverses the disease cleanly. [short pause] How to read the panel. Fasting insulin between two and six with HOMA-I-R under one point zero — metabolically clean. Protocol is on track. Keep going. Fasting insulin six to ten with normal fasting glucose — Stage two insulin resistance. The pancreas is compensating successfully but it's working. Phase one protocol — MOTS-c, exercise sensitization — is the right intervention. H-b-A-1-c will look fine here. Do not be fooled. Triglyceride to H-D-L ratio above two point zero — insulin resistance signal independent of glucose. Practitioner consensus: this single ratio off a basic lipid panel is a better predictor of metabolic mortality than total cholesterol or L-D-L. If the ratio is three to one or higher, the cellular insulin resistance is already structural — you're not catching it early. Fasting glucose above ninety with fasting insulin above ten — Stage four. The compensation is failing. This is when most patients are first diagnosed by conventional medicine. From the substrate's perspective, this is late. C-G-M post-meal spike above fifty milligrams per deciliter above baseline, taking more than two hours to return — METABOLIC INFLEXIBILITY. The pancreas can clear the glucose eventually, but the cells aren't taking it up efficiently. This is a leading indicator and shows up before fasting glucose breaks. [short pause] What's NOT happening yet. H-b-A-1-c is not your scorecard. It will lag the protocol by eight to twelve weeks because it's measuring the past ninety days of glucose binding to hemoglobin. A clean Week six fasting insulin can co-exist with a still-elevated Week six A-1-c. The fasting insulin is telling the truth; the A-1-c is reporting old news. Fasting glucose is not your scorecard either. If you started at Stage two or three, your fasting glucose was probably already normal. It can't go more normal. The win shows up in fasting insulin and HOMA-I-R dropping, not in fasting glucose changing. A normal lipid panel does not mean metabolically healthy. Triglyceride to H-D-L of two point five with normal total cholesterol is insulin resistance. Read the ratio, not the individual numbers. One C-G-M data point is meaningless. You're looking for the fourteen-day pattern: pre-meal floor, post-meal ceiling, time-to-return-to-baseline, overnight floor stability. A single spike after one bad meal is signal noise. The pattern is the signal. And C-peptide dropping is not progress. If C-peptide falls during the protocol, that's beta-cell exhaustion, not recovery. C-peptide should stay stable or rise modestly as the pancreas unloads. [short pause] The practitioner corpus describes these markers. Pull them. Re-pull them. The labs that move first are the labs that matter.